Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: web  Related to the article below (Last Update: 8/5/2008)

Judge may shutter Web site selling Olympics tix
ESPN -
AP SAN FRANCISCO -- The US Olympic Committee asked a federal judge for the second time Monday to shut down a Web site it alleges is fraudulently selling ...
Judge may shutter Web site selling Olympics tix CNN
USOC pushes for shut down of phony Olympics ticket Web site WZTV
Lawsuit: Shut down fake Olympic ticket Web sites CNN
CNN
all 115 news articles »
Expanded AccessMyHealth.org Web Site Features Surveys and ...
MarketWatch -
The AccessMyHealth.org Web site and surveys are part of a broader effort of the HCA to develop a strategy for adoption and use of online personalized health ...

TechCrunch
Mozilla leads push to reimagine Web browsers
San Francisco Chronicle,  USA -
(08-04) 19:05 PDT -- Mozilla, the group that oversees scores of volunteer programmers collaborating on the free Firefox Web browser, hopes to attract more ...
Adaptive Path Releases Aurora To ?Inspire And Engage? Community TechCrunch
all 3 news articles »
'ENTERTAINMENT TONIGHT' and MSN Unite in Web Content Deal
MarketWatch -
"Pairing ET, the #1 source for celebrity news on TV, with MSN, a top online Web destination, will create a one-stop source for celebrity and entertainment ...
'ET', MSN Ink Deal Broadcasting & Cable
all 16 news articles »
Web Developer II 30490
Seattle Times, United States -
Will be Developing/enhancing web site. Developing Windows Application in c#. skills that are required for this position are C# and web development in the ...
TrueSight Edge First To Provide End-user Monitoring for Akamai ... MarketWatch
all 11 news articles »  AKAM

VNUNet.com
Dell Seeks, May Receive 'Cloud Computing' Trademark
InformationWeek, NY -
By J. Nicholas Hoover Like the term Web 2.0, "cloud computing" is quickly becoming a meme without borders. And like the old one, the new phrase with the ...
Dell's Trademark for 'Cloud Computing' Raise Ire InternetNews.com
Dell seeks control of clouds VNUNet.com
Dell tries to trademark "cloud computing" Pocket-lint.co.uk
Washington Post - Computerworld
all 56 news articles »  DELL
Montauk Monster burning up the Web
Minneapolis Star Tribune, MN -
The so-called ?Montauk Monster? is burning up the Web. On CNN?s site, the creature copped the no. 1 story spot Monday (beating out ?Racy Photos of Toddler?s ...
Busted for a Web addiction
Houston Chronicle, United States -
My name is Ken ... and I'm a World Wide Web junkie. I wanted to see how bad I had the Internet jones, so I looked for a test on ... here we go, the Internet ...
Web chips away at China's grip on information
San Francisco Chronicle,  USA -
Blogs, forums, social networking, video sharing and other community-oriented sites - known as Web 2.0 - depend on users expressing their opinions. ...
China monitoring video Web sites more closely San Francisco Chronicle
all 3 news articles »
Web.com Reports Second Quarter 2008 Financial Results
MarketWatch -
"Despite challenging economic conditions, Web.com was able to hit the top of its quarterly revenue and earnings guidance. The operating leverage potential ...
Source: Google News

[BOOK] The Souls of Black Folk -
WEB Du Bois - 2003 - books.google.com
... THE SOULS OF BLACK FOLK WEB Du Bois Introduction and Notes by Farah [asinine Griffin
Page 2. ... " (page 146) Page 5. WEB DU BOIS THE SOULS OF BLACK FOLK ...

Measuring the Independence of Central Banks and Its Effect on Policy Outcomes -
A Cukierman, SB Web, B Neyapti - The World Bank Economic Review, 1992 - World Bank
Page 1. THE WORLD BANK ECONOMIC REVIEW. VOL. 6. NO. 1: 35J-J9J Measuring the
Independence of Central Banks and Its Effect on Policy Outcomes ...

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide … -
W Focuses, NPG Contact - The EMBO Journal, 1997 - nature.com
The EMBO Journal (1997) 16, 5572?5581, doi: 10.1093/emboj/16.18.5572. Crystal
structure of the activated insulin receptor tyrosine ...

[PDF] The World-Wide Web -
T Berners-Lee, R Cailliau, A Luotonen, HF Nielsen, … - Communications of the ACM, 1994 - computertextbook.com
... What is the World Wide Web? The World Wide Web is the total collection of Web
pages that are stored on Web servers located all over the world. ...
-

[PDF] The diameter of the world wide web -
R Albert, H Jeong, AL Barabasi - Arxiv preprint cond-mat/9907038, 1999 - arxiv.org
arXiv:cond-mat/9907038 v2 10 Sep 1999 The diameter of the world wide web Despite
its increasing role in communication, the world wide web (www) remains the ...

Clonal expansion of p 53 mutant cells is associated with brain tumour progression -
D Sidransky, T Mikkelsen, K Schwechheimer, ML … - Nature, 1992 - nature.com
... David Sidransky * , Tom Mikkelsen ? , Karl Schwechheimer ? , Mark L.
Rosenblum ? , Web Cavanee ? & Bert Vogelstein *. * The ...

[PDF] The semantic Web -
T Berners-Lee, J Hendler, O Lassila - Scientific American, 2001 - www-personal.si.umich.edu
... May 17, 2001 The Semantic Web A new form of Web content that is meaningful to computers
will unleash a revolution of new possibilities ... Web: A Research Agenda ...
-

All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral -
W Focuses, NPG Contact - The EMBO Journal, 1998 - nature.com
The EMBO Journal (1998) 17, 6776?6782, doi:10.1093/emboj/17.23.6776. All in the
family? New insights and questions regarding interconnectivity ...

The anatomy of a large-scale hypertextual Web search engine -
S Brin, L Page - Computer Networks and ISDN Systems, 1998 - Elsevier
... The anatomy of a large-scale hypertextual Web search engine ? ... Keywords: World Wide
Web; Search engines; Information retrieval; PageRank: Google ...

[CITATION] The Souls ofBlack Folk
WEB Du Bois - Three Negro Classics, 1903

Source: Google Scholar
 
 

Alzheimer’s vaccine, hopeful results from interrupted trial

 
 
In January 2002 Elan Corporation and Wyeth-Ayerst Laboratories suspended their Phase IIA clinical trial of AN1792, also known as the “ Alzheimer vaccine ” after four clinical trial participants became ill with central nervous system ( CNS ) inflammation.
The trial has been terminated based on the conclusions of the independent Safety Monitoring Committee.

However, immunotherapy against Alzheimer’s disease may still offer a promising option for slowing or even preventing this disease, according to researchers.

The study was stopped early in 2002 after a few participants developed brain inflammation. But the researchers continued to monitor the patients for up to a year after their last injection.

Results from the interrupted trial have showed that on the whole, study participants whose immune systems mounted a response against beta amyloid performed significantly better on a series of memory tests than those who received a placebo injection.

Brain scans also showed that patients who had an immune response experienced a decrease in brain size, possibly indicating the removal of built-up protein due to an immune system attack.

A smaller group of immune responders also had a decrease in levels of a protein called tau in their spinal fluid, compared with participants who received placebo, possibly indicating a slowing in the death rate of their brain cells.

“ The idea of inducing the immune system to view beta amyloid as a foreign protein, and to attack it, holds great promise, ” says Sid Gilman, director of the Michigan Alzheimer’s Disease Research Center and the head of the Data Safety Monitoring Board for both clinical trials. “ We now need to see whether we can create an immune response safely and in a way that slows the progression of Alzheimer’s disease and preserves cognition. ”

Researchers at University of Michigan are preparing to recruit participants for a phase II clinical trial to test a new Alzheimer’s immunotherapy vaccine strategy that has been through a phase I safety trial.
The phase II study, which aims to stimulate an immune attack against beta amyloid without raising brain inflammation risk, is being conducted at 30 centers in the United States and dosing has already begun at some sites.
All the trials have been funded by Elan Corporation and Wyeth Pharmaceuticals.

Rather than injecting participants with beta amyloid itself, the new trial is based on injections of humanized antibodies against part of the beta amyloid molecule.
The antibodies should help trigger the immune system to attack beta amyloid, but will be cleared by the body soon after injection. That means a series of six injections to “remind” the body to attack beta amyloid.

As in the previous study, participants will be randomly assigned to receive either antibodies or a placebo; neither they nor the researchers will know what they got until the 27-month study ends. The new study will enroll 180 adults between the ages of 50 and 85 who have a diagnosis of probable Alzheimer’s and a caregiver who can bring them to frequent appointments for brain imaging, neuropsychological testing and blood tests.
Some participants will have additional blood tests or spinal fluid tests; they will also have a slightly higher chance of getting antibodies.

Gilman explains that the concept of vaccinating against beta amyloid was first proposed by scientist Dale Schenk.
In the late 1990s, Schenk and his colleagues showed that vaccination from birth could prevent mental decline in mice that had been bred to develop Alzheimer’s-like disease.
They and others also showed that older mice receiving the vaccine appeared to regain cognitive function.
The exciting animal research results led to a Phase I trial in humans with Alzheimer’s disease that showed no ill effects, and then the Phase II trial that was stopped early.

In one study published in the journal Neurology, 59 of the 300 participants who received at least one injection of beta amyloid developed significant quantities of antibodies against it in their blood. All but three of these 59 patients, who were called “antibody responders,” had received at least two injections before the study was stopped; nine of them had received three injections. Thirteen of the 59 developed some level of encephalitis, as well as five of the patients whose immune systems did not react as strongly.

Although the study showed no statistical difference between the placebo and beta amyloid groups in results on five tests often used in patients with Alzheimer’s disease and other dementias, there were significant differences on a battery of other tests that measure memory, executive function and verbal ability. The difference reached statistical significance in immune responders compared with patients who received placebo.

Spinal fluid samples taken from 21 of the participants in the study before it was stopped also reveal some intriguing hints. The 11 immune responders had a significant decline in levels of the tau protein, a structural protein considered a hallmark of cell death in the brain, when compared with 10 participants who received placebo.

Also encouraging, but not conclusive, is evidence from autopsies conducted on Phase I and II trial participants who have died in the years since the studies were completed or stopped, Gilman says. “ Three participants died of causes unrelated to the vaccination, two of whom had developed encephalitis and one other did not develop encephalitis. All had large patches of their brains where beta amyloid had apparently been cleared out, the tangles of tau protein were still visible,” he explains.

The first three cases from the Phase II trial have been published in separate papers. The fourth case of a patient in the Phase I trial was recently presented at an international meeting. The participant received four injections of beta amyloid and had evidence in the brain tissue of immune system cells ( microglia ) removing beta amyloid protein, a sign of an active immune response.

The MRI images taken of study participants before and after their injections also showed shrinking of brain tissue that was more pronounced in the 45 immune responders than in 57 placebo patients.

“ This was the opposite of what we expected, and it’s exciting because it was associated with relative preservation of memory, ” says Gilman. “ It may be that beta amyloid was taken out of the brain as a result of the immune response, and that the protein carried water with it, causing further shrinkage. ”

Source: University of Michigan Health System, 2005


Clinical effects of beta A immunization ( AN1792 ) in patients with AD in an interrupted trial, Neurology ; 64: 1553

Effects of beta A immunization ( AN1792 ) on MRI measures of cerebral volume in Alzheimer disease, Neurology ; 64: 1563
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News2 ; News3 ; News4 ; News5 ; News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page